Functional MRI for anticancer therapy assessment

被引：85

作者：

Padhani, AR ^{[1
]}

机构：

[1] Mt Vernon Hosp, Paul Strickland Scanner Ctr, Northwood HA6 2RN, Middx, England

来源：

EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷 / 16期

关键词：

magnetic resonance imaging; tumour; angiogenesis; treatment response;

D O I：

10.1016/S0959-8049(02)00388-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anticancer drug discovery and development are experiencing a paradigm shift from cytotoxic therapies to more selective therapies that target underlying oncogenic abnormalities. Many newer therapies are cytostatic, for which objective tumour shrinkage is an inappropriate response parameter. There is a growing need to develop surrogate endpoints of drug efficacy to speed up the process of finding effective drug combinations for phase III trials. This review focuses on the developing field of functional magnetic resonance imaging (MRI) and its potential applications in the pharmacodynamic evaluation of existing and new cancer therapeutics. Dynamic contrast enhanced MRI, which is currently being used to evaluate anti-angiogenic, and anti-vascular agents in human trials will be reviewed in detail. The requirements that must be met before incorporating functional MRI techniques into clinical protocols are also discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：2116 / 2127

页数：12

共 119 条

[1] Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging [J].

Abramovitch, R ;

Frenkiel, D ;

Neeman, M .

MAGNETIC RESONANCE IN MEDICINE, 1998, 39 (05) :813-824

[2]

Abramovitch R, 1999, CANCER RES, V59, P5012

[3]

ARONEN HJ, 1995, ACTA RADIOL, V36, P520

[4] CEREBRAL BLOOD-VOLUME MAPS OF GLIOMAS - COMPARISON WITH TUMOR GRADE AND HISTOLOGIC-FINDINGS [J].

ARONEN, HJ ;

GAZIT, IE ;

LOUIS, DN ;

BUCHBINDER, BR ;

PARDO, FS ;

WEISSKOFF, RM ;

HARSH, GR ;

COSGROVE, GR ;

HALPERN, EF ;

HOCHBERG, FH ;

ROSEN, BR .

RADIOLOGY, 1994, 191 (01) :41-51

[5] Gliomas: Correlation of magnetic susceptibility artifact with histologic grade [J].

Bagley, LJ ;

Grossman, RI ;

Judy, KD ;

Curtis, M ;

Loevner, LA ;

Polansky, M ;

Detre, J .

RADIOLOGY, 1997, 202 (02) :511-516

[6] Staging urinary bladder cancer after transurethral biopsy: Value of fast dynamic contrast-enhanced MR imaging [J].

Barentsz, JO ;

Jager, GJ ;

vanVierzen, PBJ ;

Witjes, JA ;

Strijk, SP ;

Peters, H ;

Karssemeijer, N ;

Ruijs, SHJ .

RADIOLOGY, 1996, 201 (01) :185-193

[7] Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging [J].

Barentsz, JO ;

Berger-Hartog, O ;

Witjes, JA ;

Hulsbergen-van der Kaa, C ;

Oosterhof, GON ;

VanderLaak, JAWM ;

Kondacki, H ;

Ruijs, SHJ .

RADIOLOGY, 1998, 207 (03) :791-797

[8] Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts [J].

Bhujwalla, ZM ;

Artemov, D ;

Natarajan, K ;

Ackerstaff, E ;

Solaiyappan, M .

NEOPLASIA, 2001, 3 (02) :143-153

[9] Role of radionuclide imaging in trials of antiangiogenic therapy [J].

Blankenberg, FG ;

Eckelman, WC ;

Strauss, W ;

Welch, MJ ;

Alavi, A ;

Anderson, C ;

Bacharach, S ;

Blasberg, RG ;

Graham, MM ;

Weber, W .

ACADEMIC RADIOLOGY, 2000, 7 (10) :851-867

[10] In vivo detection and imaging of phosphatidylserine expression during programmed cell death [J].

Blankenberg, FG ;

Katsikis, PD ;

Tait, JF ;

Davis, RE ;

Naumovski, L ;

Ohtsuki, K ;

Kopiwoda, S ;

Abrams, MJ ;

Darkes, M ;

Robbins, RC ;

Maecker, HT ;

Strauss, HW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6349-6354

← 1 2 3 4 5 6 7 8 9 10 →